Remove 2024 Remove Biopharma Remove Mergers and acquisition activities
article thumbnail

Pharmaceutical Outsourcing Evolution: The Rise of Clinical Peripheral Services

Frost & Sullivan

The Expanding Role of Clinical Contract Peripheral Services As the pharmaceutical and biopharma industries recalibrate after the COVID-19 pandemic, clinical trial outsourcing has surged, creating significant opportunities for contract research organizations (CROs). billion in 2024, is projected to grow at a CAGR of 10.7%, reaching $122.13

article thumbnail

JP Morgan Healthcare Conference 2025: Key Growth Opportunities Shaping the Future of Pharma and Biotechnology

Frost & Sullivan

Key Trends and Growth Opportunities Focus on Mergers & Acquisitions (M&A) Driving Industry Consolidation M&A activity emerged as a dominant theme at JPM 2025, with deals exceeding $18 billion announced during the conference. billion acquisition of Scorpion Therapeutics , adding a promising PI3K inhibitor program.